Navigation Links
Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics

ophos. In vitro, TRO19622 promotes motor neuron survival in the absence of trophic support in a dose-dependent manner. In preclinical models in vivo, TRO19622 rescues motor neurons from axotomy-induced cell death in neonates and promotes nerve regeneration following sciatic nerve crush. Furthermore, in the SOD1G93A model of familial ALS, TRO19622 treatment improves motor performance, delays the onset of the clinical disease, and extends survival.

TRO19622 binds directly to two components of the mitochondrial permeability transition pore: the voltage-dependent anion channel (VDAC) and the translocator protein (or peripheral benzodiazepine receptor), suggesting a potential mechanism for its neuroprotective activity.

TRO19622 has successfully completed Phase I/Ib studies in both healthy volunteers and ALS patients demonstrating the product is well tolerated, has an excellent safety profile and that once-a-day dosing achieves the predicted exposure level required for efficacy, based on preclinical models. These data support the further clinical evaluation of TRO19622 as a potential treatment for ALS.

"Trophos is proud to have this body of work accepted for publication in a well recognized journal such as JPET," said Rebecca Pruss, CSO at Trophos. "Given the significant unmet medical need in ALS, it is tremendously encouraging that TRO19622 promotes the survival of motor neurons in this extensive battery of preclinical models. These studies, along with the excellent clinical safety profile of TRO19622, provide the basis upon which Trophos plans to initiate a pivotal Phase II/III trial to establish the clinical efficacy of TRO19622 in ALS patients."

Pruss added: "Moreover, we are particularly excited that there is increasing preclinical evidence that the mitochondria-mediated mechanism of action of TRO19622, and other compounds in this class, will have huge commercial potential in other chronic neurological disorders, such as neuropathic pain,
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
6. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
7. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
8. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
9. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
10. JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. ... , the Canadian Medical Association (CMA) voted on ... any plant material, including medicinal cannabis. Bedrocan Cannabis Corp., ... supportive of the CMA motion. The CMA ... particular hazards associated with smoking any plant material, including ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... Research Products: Opportunities, Tools & Technologies" report to ... stem cell research products or you wish to expand ... lucrative this market is. The authors know you want ... effectively to scientists, to generate improved revenues and take ...
(Date:8/22/2014)... Mich. , Aug. 22, 2014  Dr. ... Who with the Diamond Lifetime Achievement Award in the ... as CEO of Cardiovascular Clinical Associates. Dr. ... in managing all major aspects of the business; overseeing ... well as primary coronary intervention. In addition, he is ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... CARLSBAD, Calif., Oct. 18 Excaliard Pharmaceuticals, Inc. ... as Chairman of its Board of Directors. Mr. ... years of experience in successfully developing and commercializing ... field.  Excaliard Pharmaceuticals, Inc. is a biotechnology company ...
... Bend Research Inc. ( www.bendres.com ), a ... announced today it has extended its drug discovery ... Company ( www.bms.com ) (NYSE: BMY ... Under the terms of the 3-year agreement, Bristol-Myers ...
Cached Medicine Technology:Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board 2Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb 2
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... that uses university-proven research to show people how they can ... lean muscle in only a matter of weeks has caught ... , “Ben Pakulski is one of the most well-known bodybuilders ... get the body he has today, that in itself is ...
(Date:8/22/2014)... a complex autoimmune disease that affects 1 to ... only cope with pain, disability and joint disfigurements, ... family life and marital functioning. While many pharmacological ... disability is common. In addition, some patients avoid ... side effects. Because of this, there is interest ...
(Date:8/22/2014)... 2014 Testosterone treatment lawsuits ( ... courts on behalf of men who allegedly suffered ... prescription low testosterone therapies, Bernstein Liebhard LLP reports. ... filed against Pfizer Inc. on July 31st by ... issues due to his use of Depo-Testosterone. (Case ...
(Date:8/22/2014)... UK (PRWEB) August 22, 2014 The ... recent past, specifically in the developing world, has led ... and the number of deaths due to AIDS globally. ... declining, the number of new patients becoming affected by ... conscious efforts being undertaken by all related organisations and ...
(Date:8/22/2014)... Ohio (PRWEB) August 22, 2014 Dayton Children's ... care tower as part of a $141 million campus renewal. ... patient care tower were unveiled to the public. , ... facilities plan that will create a campus that meets the ... future. These new care spaces will embody Dayton Children’s unique ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... cells, stem cells derived from human placenta left over ... when they interacted with one kind of melatonin receptor, ... cells were transplanted into laboratory test tube and animal ... perform similarly when interacting with melatonin receptor MT2. ...
... 1, 2011) Positron emission tomography (PET) can ... kinase inhibitor vandetanib, helping to define the therapy ... according to research published in the February issue ... Currently being tested in clinical trials, vandetanib inhibits ...
... Society for Therapeutic Radiology and Oncology (ESTRO), the European ... for Medical Oncology (ESMO) in collaboration with other European ... on the 3rd International Conference on innovative approaches In ... on multidisciplinarity and innovation, this meeting will specifically cover ...
... and ultrasound can mean more targeted breast biopsies for ... and possibly saving those patients from undergoing a second ... Patients with early breast cancer undergo a sentinel lymph ... said Dr. Ali Sever, lead author of the study. ...
... -- Among injection drug users, new cases of HIV infection ... number of new infections from the hepatitis C virus have ... The findings suggest that efforts -- such as needle exchange ... of infectious diseases have been successful against HIV but more ...
... professionals have talked about youth pitching injuries and the stress ... new, 10-year study published in the February issue of the ... participants who pitched more than 100 innings in a year ... study proved a direct link between innings pitched in youth ...
Cached Medicine News:Health News:Transplanted human placenta-derived stem cells show therapeutic potential in stroke models 2Health News:PET scans may allow early prediction of response to targeted therapy of thyroid cancer 2Health News:3rd international conference on innovative approaches in head and neck oncology 2Health News:Microbubble ultrasound and breast biopsies 2Health News:Infectious Disease Experts Call for More Focus on Hepatitis C 2Health News:New 10-year study confirms too many pitches strike out youth athletes early 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: